Pfizer has licensed Halozyme Therapeutics' Enhanze technology, which the pharmaceutical giant plans to combine with its biologics. The technology allows drugs that would otherwise have to be administered intravenously or require multiple injections to be delivered subcutaneously -- just below the surface of the skin.
Two therapeutic targets in primary care and specialty care indications have already been identified, for which Pfizer will pay Halozyme $8 million. The license also allows Pfizer to select four additional targets upon payment of additional undisclosed fees.
Halozyme is eligible to receive additional payments of up to $507 million if Pfizer achieves specific development, regulatory, and sales-based milestones.
The biotech has licensed the Enhanze technology to four other companies: Baxter , Roche , Viropharma , and Interexon.
The article Pfizer Licenses Halozyme's Enhanze Technology originally appeared on Fool.com.Fool contributor Brian Orelli has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.